Akums Drugs and Pharmaceuticals has secured approval from Drugs Controller General of India for its ground-breaking triple combination diabetes treatment. Sitagliptin 100, pioglitazone 15 and metformin 1000/500 comes as a more advanced treatment for diabetes, with much more efficacy and precision than monotherapy drugs that are currently in the market.
Sitagliptin 100, pioglitazone 15 and metformin 1000/500 is specifically formulated for the treatment of diabetes and offers a number of pharmacological advantages.
The combination contains three distinctly active formulations such as metformin, a glucose-lowering agent often prescribed as a first-line therapy for type-2 diabetes (T2D).
"We have carefully studied the pharmacological properties of these formulations and with sitagliptin 100, pioglitazone 15 and metformin 1000/500, we found the right blend for our triple-active combination. This is going to better serve anti-diabetic patients who require better treatment without necessarily swallowing multiple drugs. The approval is a boost because it shows that we followed all laid down procedures, and the drug is fit for use by patients who need relief from the impacts of not just type-2 diabetes, Patient convenience and dosage compliance " said Sanjeev Jain, joint managing director, Akums Drugs & Pharmaceuticals.
The bi-layered combination was formulated following well-researched processes and operations, as well as adherence to pharmacological guidelines. Speaking on the approval, Sandeep Jain, jt. managing director, Akums Drugs & Pharmaceuticals, noted that the renoprotective effects of drugs like metformin coupled with the functional and corrective influence of pioglitazone on beta-cell and metabolic syndrome, and the stability of sitagliptin, make an effective solution for diabetes.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!